News and communications

Antimicrobial resistance to Group B Streptococcus (GBS) antibiotics is growing. This puts newborns at risk. VDEC is supporting a new vaccine to cut antibiotic use

• Updated: 23 May 2024

This initiative signals an important step towards a new regulatory framework for medical devices in Great Britain which protects public health, ensures access to MedTech innovations, and maintains an attractive market for in…

• Updated: 21 May 2024

The Medicines and Healthcare products Regulatory Agency (MHRA) has today (21 May 2024) launched a four-week consultation which will support improved safety for certain high risk in vitro diagnostic (IVD) devices.

• Updated: 21 May 2024

Backed by a new award of £1.8 million, the Medicines and Healthcare products Regulatory Agency (MHRA) is to establish a dedicated team to provide regulatory scientific support for innovators creating novel antimicrobials and…

• Updated: 16 May 2024

Two pharmacists who sold ‘industrial’ quantities of Class C controlled drugs were yesterday sentenced to two years’ imprisonment each, suspended for 24 months, at Southwark Crown Court following an investigation by the Crimi…

• Updated: 16 May 2024

Following MHRA approval of a clinical trial, a study on Nuwiq, a recombinant FVIII therapy for the treatment of haemophilia A, can proceed.

• Updated: 15 May 2024

New 10-year plan to expand and improve the drug and alcohol workforce published.

• Updated: 14 May 2024

The changes will allow pharmacists to spend more time with patients, levelling the playing field between smaller pharmacies and larger chains.

• Updated: 13 May 2024

The Medicines and Healthcare products Regulatory Agency (MHRA) has today (9 May 2024) launched AI Airlock, its new regulatory sandbox for AI as a Medical Device (AIaMD).

• Updated: 9 May 2024

An MHRA and NICE partnership, funded by Wellcome, is addressing key challenges for regulating and evaluating digital mental health technologies (DMHTs) with input from patients, the public and mental health professionals.

• Updated: 7 May 2024

The MHRA has authorised cabotegravir as 30 mg tablets and as a 600 mg long-acting injection administered every two months

• Updated: 3 May 2024

Further measures to be introduced to ensure patients who are prescribed montelukast for the treatment of asthma are informed of the risk of neuropsychiatric reactions

• Updated: 29 April 2024

The MHRA will introduce a patient alert card to increase awareness among men taking finasteride about potential psychiatric and sexual side effects

• Updated: 29 April 2024

DASA seeks innovations to provide protection for land based assets from air attacks

• Updated: 17 April 2024

The Medicines and Healthcare products Regulatory Agency (MHRA) has today (9 April 2024) approved the medicine fosdenopterin (Nulibry) to treat the genetic disease Molybdenum Cofactor Deficiency (MoCD) Type A

• Updated: 9 April 2024

Batches of some products made by Legency Remedies Pvt Ltd have been found to contain a bacteria called Ralstonia pickettii (R. pickettii). All potentially affected batches are being recalled following an MHRA investigation.

• Updated: 5 April 2024

Charges for NHS prescriptions, wigs and fabric supports will increase on 1 May 2024.

• Updated: 5 April 2024

Ventilators, oxygen concentrators, pumps and monitors among kit donated to Ukraine.

• Updated: 5 April 2024

The MHRA has approved the combined antibiotic cefepime/enmetazobactam (Exblifep 2 g/0.5 g powder for concentrate for solution for infusion)

• Updated: 4 April 2024

Following MHRA approval of a clinical trial, early breast cancer patients on endocrine-based therapy can benefit from a study with camizestrant.

• Updated: 28 March 2024